Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.42 |
| ▸ | PRCP | P42785 | 7/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | F11 | P03951 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15711257 | 1.00 | HPGDS (0.46) | HPGDSCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL15127682 | 1.00 | HPGDS (0.46) | HPGDSCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL14273516 | 1.00 | HPGDS (0.46) | HPGDSCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL12159995 | 1.00 | HPGDS (0.46) | HPGDSCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL17563565 | 1.00 | HPGDS (0.46) | HPGDSCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL11982063 | 1.00 | HPGDS (0.46) | HPGDSCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL13635812 | 1.00 | HPGDS (0.46) | HPGDSCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL18870539 | 0.95 | HPGDS (0.43) | HPGDSCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL14706595 | 0.94 | HPGDS (0.42) | HPGDSCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL17253523 | 0.94 | HPGDS (0.43) | HPGDSCYP3A4CYP2C9KCNH2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138215-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100303755-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100303755-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | HPGDS 582/4885CYP3A4 1107/4885CYP2C9 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.